<DOC>
	<DOCNO>NCT01625689</DOCNO>
	<brief_summary>In Phase II randomize controlled clinical trial , generally healthy male female child 24 59 month age enrol Kamalapur ( Dhaka ) , Bangladesh . The study expect continue least 6 month follow vaccination . The experimental intervention Serum Institute India Ltd 's Trivalent , Seasonal Live Attenuated Influenza Vaccine ( SIIL LAIV ) . The study vaccine formulate accord WHO recommendation 2011-2012 Northern Hemisphere influenza season . The SIIL LAIV administer 0.5 ml intranasal dose ( one spray 0.25 ml per nostril ) via reusable sprayer device single-use nozzle produce fine mist primarily deposit nose nasopharynx . The comparator vaccine inactive placebo identical appearance active vaccine . The primary study hypothesis LAIV safe well tolerated child age 24 59 month Bangladesh . A secondary hypothesis LAIV immunogenic among child receive study vaccine compare child receive placebo .</brief_summary>
	<brief_title>Safety Immunogenicity Single Dose Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female child least 24 month age old 59 month age time study vaccination A child whose parent guardian 's primary residence , time study vaccination , within Kamalapur surveillance site catchment area intend present area duration trial A child whose parent legal guardian willing provide write informed consent prior participant 's study vaccination Has serious chronic disease include progressive neurologic disease , tuberculosis , Down 's syndrome cytogenetic disorder , know suspected disease immune system Is receive immunosuppressive agent include systemic corticosteroid two week prior study vaccination Has history document hypersensitivity eggs component vaccine ( include gelatin , sorbitol , lactalbumin chicken protein ) , lifethreatening reaction previous influenza vaccination Is receive aspirin therapy aspirincontaining therapy currently two week Lives household somebody currently participate respiratory vaccination antiviral study Has current past participation ( within 2 month trial enrollment visit ) clinical trial involve drug biologic activity respiratory disease Has condition determine investigator likely interfere evaluation vaccine significant potential health risk child</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Influenza , Human</keyword>
	<keyword>Live Attenuated Influenza Vaccine</keyword>
</DOC>